Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Disease Using the PET Ligand [18F]-PI-2620
NCT05456503Phase 3Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Sep 2022
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 3 trial of 18F-PI-2620 in Fronto-temporal lobar degeneration (FTLD), Alzheimer's disease (AD), sponsored by University of Pennsylvania. Started Sep 2022; status: recruiting.
02
Drugs
18F-PI-2620
03
Conditions
Fronto-temporal lobar degeneration (FTLD)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05456503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456503.